Chad May
Chief Scientific Officer Orum Therapeutics, Inc.
Seminars
Thursday 29th October 2026
Next-Generation Degrader Antibody Conjugates
9:00 am
- Our next-generation Degrader Antibody Conjugates (DAC) are designed to improve safety and efficacy through advanced antibody and linker engineering
- DACs combine the tissue selectivity of antibody-mediated delivery with the well-validated catalytic mechanism of targeted protein degradation
- DACs offer opportunities to expand beyond conventional cytotoxic ADC payloads
